Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5072	915296-00-3

Description:

Molecule	Description
Synonyms: elotuzumab empliciti BMS-901608 HuLuc63	a humanized monoclonal antibody that selectively targets glycoproteins expressed on myeloma cells Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

elotuzumab
empliciti
BMS-901608
HuLuc63

a humanized monoclonal antibody that selectively targets glycoproteins expressed on myeloma cells

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
50	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company
Sept. 28, 2016	PMDA	Bristol-Myers Squibb
May 11, 2016	EMA	Bristol-Myers Squibb
Nov. 30, 2015	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	219.81	24.78	98	3329	106772	90518248
Plasma cell myeloma	214.68	24.78	74	3353	40754	90584266
Neutropenia	74.13	24.78	64	3363	224840	90400180
Platelet count decreased	68.84	24.78	50	3377	136919	90488101
Pneumonia	61.47	24.78	96	3331	637963	89987057
Cytomegalovirus infection	53.22	24.78	24	3403	26578	90598442
Paraproteinaemia	52.50	24.78	9	3418	248	90624772
Death	51.44	24.78	74	3353	456477	90168543
Plasma cell myeloma recurrent	48.80	24.78	14	3413	4214	90620806
Thrombocytopenia	48.61	24.78	49	3378	208676	90416344
Anaemia	48.50	24.78	63	3364	352739	90272281
Lymphocyte count decreased	46.91	24.78	24	3403	35026	90589994
Pyrexia	45.86	24.78	86	3341	660399	89964621
Neutrophil count decreased	45.00	24.78	30	3397	71502	90553518
Febrile infection	43.50	24.78	11	3416	2058	90622962
Pneumococcal sepsis	41.07	24.78	9	3418	909	90624111
Pneumonia pneumococcal	35.95	24.78	10	3417	2692	90622328
Diarrhoea	33.52	24.78	94	3333	939096	89685924
Neuropathy peripheral	31.56	24.78	32	3395	136938	90488082
Febrile neutropenia	29.42	24.78	33	3394	158316	90466704
Toxic shock syndrome	29.29	24.78	7	3420	1037	90623983
Cytomegalovirus infection reactivation	29.12	24.78	11	3416	7789	90617231
Sepsis	27.63	24.78	34	3393	179780	90445240
Beta haemolytic streptococcal infection	27.55	24.78	8	3419	2511	90622509

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	140.41	25.10	104	4278	108296	42508657
Plasma cell myeloma	124.33	25.10	71	4311	47507	42569446
Pneumonia	108.77	25.10	171	4211	421978	42194975
Neutropenia	64.19	25.10	90	4292	199341	42417612
Febrile infection	40.83	25.10	14	4368	2757	42614196
Platelet count decreased	40.75	25.10	60	4322	138521	42478432
Keratopathy	39.45	25.10	10	4372	688	42616265
Squamous cell carcinoma of skin	38.64	25.10	21	4361	12705	42604248
Neuropathy peripheral	35.71	25.10	48	4334	101805	42515148
Cytomegalovirus infection reactivation	35.49	25.10	19	4363	11159	42605794
Campylobacter gastroenteritis	35.08	25.10	10	4372	1075	42615878
Plasma cell myeloma refractory	32.50	25.10	10	4372	1400	42615553
Plasma cell myeloma recurrent	30.90	25.10	14	4368	5743	42611210
Sepsis	30.75	25.10	65	4317	199269	42417684
Factor VII deficiency	30.52	25.10	5	4377	35	42616918
Pyrexia	30.37	25.10	99	4283	393943	42223010
Anaemia	29.78	25.10	79	4303	280199	42336754
Pneumonia mycoplasmal	28.91	25.10	8	4374	772	42616181
White blood cell count decreased	28.47	25.10	45	4337	110351	42506602
Pneumonia respiratory syncytial viral	28.16	25.10	9	4373	1425	42615528
Respirovirus test positive	27.25	25.10	5	4377	72	42616881
Visceral leishmaniasis	25.81	25.10	8	4374	1146	42615807

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	320.42	25.25	173	6635	174394	110408097
Plasma cell myeloma	262.78	25.25	110	6698	62826	110519665
Pneumonia	161.18	25.25	231	6577	876483	109706008
Neutropenia	140.22	25.25	142	6666	374478	110208013
Platelet count decreased	108.06	25.25	99	6709	230344	110352147
Plasma cell myeloma recurrent	89.19	25.25	28	6780	7014	110575477
Anaemia	88.28	25.25	136	6672	546950	110035541
Pyrexia	77.20	25.25	170	6638	898095	109684396
Thrombocytopenia	75.75	25.25	100	6708	348785	110233706
Neutrophil count decreased	70.77	25.25	59	6749	120882	110461609
Cytomegalovirus infection reactivation	69.60	25.25	30	6778	18303	110564188
Sepsis	62.21	25.25	88	6720	327258	110255233
Plasma cell myeloma refractory	57.17	25.25	15	6793	1986	110580505
White blood cell count decreased	54.81	25.25	69	6739	229321	110353170
Lymphocyte count decreased	53.61	25.25	37	6771	57206	110525285
Febrile infection	53.48	25.25	17	6791	4431	110578060
Death	50.77	25.25	124	6684	698745	109883746
Cytomegalovirus infection	50.53	25.25	35	6773	54409	110528082
Paraproteinaemia	47.09	25.25	10	6798	531	110581960
Neuropathy peripheral	46.14	25.25	56	6752	179221	110403270
Septic shock	43.48	25.25	51	6757	157477	110425014
Febrile neutropenia	43.07	25.25	73	6735	316694	110265797
Keratopathy	42.65	25.25	11	6797	1362	110581129
Atrial fibrillation	38.15	25.25	58	6750	229584	110352907
Plasma cell leukaemia	38.08	25.25	11	6797	2077	110580414
Squamous cell carcinoma of skin	36.94	25.25	19	6789	17184	110565307
Campylobacter gastroenteritis	34.46	25.25	10	6798	1919	110580572
COVID-19	33.98	25.25	57	6751	245003	110337488
Cytokine release syndrome	32.46	25.25	30	6778	70276	110512215
Pancytopenia	32.10	25.25	51	6757	209562	110372929
Pneumocystis jirovecii pneumonia	31.72	25.25	24	6784	42711	110539780
Deep vein thrombosis	28.59	25.25	39	6769	139848	110442643
Factor VII deficiency	28.12	25.25	5	6803	103	110582388
COVID-19 pneumonia	27.88	25.25	21	6787	37122	110545369
Bacteraemia	27.54	25.25	22	6786	42368	110540123
Acute myeloid leukaemia	27.40	25.25	21	6787	38089	110544402
Pulmonary embolism	27.25	25.25	48	6760	214426	110368065
Respirovirus test positive	27.05	25.25	5	6803	129	110582362
Listeriosis	26.73	25.25	9	6799	2805	110579686
Basal cell carcinoma	26.27	25.25	22	6786	45248	110537243
Human metapneumovirus test	26.09	25.25	3	6805	0	110582491

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FX08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates
FDA CS	M0001357	Antibodies, Monoclonal
MeSH PA	D000970	Antineoplastic Agents
FDA MoA	N0000192337	SLAMF7-directed Antibody Interactions
FDA EPC	N0000192338	SLAMF7-directed Immunostimulatory Antibody
CHEBI has role	CHEBI:35610	antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs

amivantamab belantamab mafodotin blinatumomab brentuximab vedotin catumaxomab datopotamab deruxtecan elranatamab enfortumab vedotin epcoritamab gemtuzumab ozogamicin glofitamab ipilimumab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Multiple myeloma	indication	109989006	DOID:9538
Relapse multiple myeloma	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
SLAM family member 7	Membrane receptor	Q9NQ25	SLAF7_HUMAN	ANTIBODY BINDING	Kd	8.05		IUPHAR	DRUG LABEL

External reference:

ID	Source
1351PE5UGS	UNII
4035187	VANDF
C1832049	UMLSCUI
CHEBI:750089	CHEBI
CHEMBL1743010	ChEMBL_ID
DB06317	DRUGBANK_ID
9074	INN_ID
C546027	MESH_SUPPLEMENTAL_RECORD_UI
8361	IUPHAR_LIGAND_ID
1726104	RXNORM
237251	MMSL
31305	MMSL
d08403	MMSL
016608	NDDF
715660001	SNOMEDCT_US
781350003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2291	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	300 mg	INTRAVENOUS	BLA	25 sections
EMPLICITI	HUMAN PRESCRIPTION DRUG LABEL	1	0003-4522	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	400 mg	INTRAVENOUS	BLA	25 sections

Ask DrugCentral

Try a sample question

elotuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: